Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Pharmacotherapy is an effective, evidence-based treatment for people living with obesity, as part of a long-term, ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...

Patients who have undergone weight-loss treatment need better support after their treatment ends to maintain a healthy weight ...

JOANNA Higgenbottom spent almost $800 (£600) each month on takeaways, before Mounjaro helped her shed 23st. The 60-year-old ...

Comedian Amy Schumer posted a photo with a walker on social media after laminectomy surgery to address chronic back pain from previous surfing injury.